SAM
ALNY icon

Silvercrest Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Silvercrest Asset Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,429
Closed -$3.45M – 849
2026
Q1 		$3.45M Buy
10,429
+19
+0.2% +$6.47K 0.02% 471
2025
Q4 		$4.14M Sell
10,410
-397
-4% -$176K 0.03% 457
2025
Q3 		$4.93M Buy
10,807
+556
+5% +$226K 0.03% 426
2025
Q2 		$3.34M Buy
10,251
+430
+4% +$119K 0.02% 476
2025
Q1 		$2.65M Buy
9,821
+4,930
+101% +$1.27M 0.02% 502
2024
Q4 		$1.15M Buy
+4,891
New +$1.29M 0.01% 598

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Silvercrest Asset Management's ALNY Position: Q2 2026 in Review

Silvercrest Asset Management sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2026, closing a stake of 10,429 shares — an estimated $3.45M sold.

Silvercrest Asset Management first reported a position in ALNY in Q4 2024 and held it in 6 quarters. The position peaked at $4.93M in Q3 2025. 784 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Silvercrest Asset Management reported no remaining Alnylam Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Silvercrest Asset Management sold 10,429 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $3.45M.
  • Silvercrest Asset Management first reported a position in Alnylam Pharmaceuticals in Q4 2024 and held it in 6 quarters.
  • Silvercrest Asset Management's Alnylam Pharmaceuticals position peaked at $4.93M in Q3 2025.
  • 784 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Silvercrest Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.